On June 28, 2024, starting at 17:30, our CEO/CSO Satoshi Tamaki will be presenting at a collaborative event hosted by the Life Science Innovation Network Japan (LINK-J) and Merck KGaA. The event, titled “Pioneering Drug Discovery DX: Exploring the Latest Trends from Multiple Perspectives”, will be held in a hybrid format and requires prior registration for participation. The event will be conducted in Japanese. Tamaki’s presentation, titled “Utilizing Evolutionary Molecular Engineering and Large Language Models in Antibody Design”, will showcase examples of our company’s AI-driven de novo discovery and optimization of antibodies.

For more details and to register for the event, please visit the event website (link). We look forward to your participation.